Skip to main content
SpringerLink
Log in

Zyn-Linker delivery of antirheumatic agents

  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

Despite our increasing ability to manage rheumatoid arthritis through systemic medication, refractory joints require local administration of more aggressive therapy in a substantial number of patients. These studies tested whether a new class of molecules designated Zyn-LinkersTM could deliver and retain therapeutics in a joint. Zyn-Linkers are synthetic lipidlike molecules designed to insert into cell membranes and enhance drug delivery to cells. After intra-articular injection into the knee of NZW rabbits, Zyn-Linkers bound rapidly and homogenously to synovial lining cells. Chelating Zyn-Linkers which contained Re-186 or Y-90 were synthesized to evaluate localization and retention after intra-articular injection. Initial studies using Re-186 Zyn-Linker gave excellent localization as evaluated by whole-body imaging: counts in the knee region represented >90% of counts present in the whole body for at least 4–6 days postinjection. Similar results were obtained using a Y-90 Zyn-Linker and this agent was used for biodistribution studies due to its greater stability and ease of preparation. Efficacy and safety of Y-90 Zyn-Linker as a potential radiation synovectomy agent were estimated by extrapolation of biodistribution data to humans. A therapeutically effective dose of 8,000 cGy to synovium was calculated to require intra-articular injection of 3.4 mCi Y-90 Zyn-Linker, a value less than or equal to doses of particulate Y-90 agents used clinically in Europe. The predicted safety profile for Y-90 Zyn-Linker was excellent, with estimated doses to nontarget organs and tissues falling well within FDA-recommended safety levels for research-only radiopharmaceuticals. In addition to exhibiting desirable localization and retention properties, Zyn-Linkers may also be synthesized to release antirheumatic drugs such as methotrexate at controlled rates. This suggests substantial potential for these drug delivery molecules as chemical synovectomy agents which may be used concurrently with systemic chemotherapy to improve management of refractory joints.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gatter RA: Arthrocentesis technique and intrasynovial therapy; in McCarty DJ, Koopman WJ (eds): Arthritis and Allied Conditions, ed 12. Philadelphia, Lea & Febiger, 1993, pp 711–720.

    Google Scholar 

  2. Gschwend N: Synovectomy; in Kelley WN, Harris ED Jr, Ruddy S, Sledge CB (eds): Textbook of Rheumatology. Philadelphia, Saunders, 1989, pp 1934–1961.

    Google Scholar 

  3. Deutsch E, Brodack JW, Deutsch KF: Radiation synovectomy revisited. Eur J Nucl Med 1993;20:1113–1127.

    Article  PubMed  CAS  Google Scholar 

  4. Zuckerman JD, Sledge CB, Shortkroff S, Venkaesan P: Treatment of rheumatoid arthritis using radiopharmaceuticals. Nucl Med Biol 1987;14:211–218.

    CAS  Google Scholar 

  5. Johnson LS, Yanch JC: Absorbed dose profiles for radionuclides of frequent use in radiation synovectomy. Arthritis Rheum 1991;34:1521–1530.

    PubMed  CAS  Google Scholar 

  6. Gumpel JM, Beer TC, Crawley JCW, Farran HEA: Yttrium 90 in persistent synovitis of the knee—A single centre comparison: The retention and extra-articular spread of four Y radiocolloids. Br J Radiol 1975;48:377–381.

    Article  PubMed  CAS  Google Scholar 

  7. Chinol M, Vallabhajosula S, Zuckerman JD, Goldsmith SJ: In vivo stability of ferric hydroxide macroaggregates (FHMA): Is it a suitable carrier for radionuclides used in synovectomy? Int J Radiat Appl Instrum 1990;17:479–486.

    CAS  Google Scholar 

  8. Dunscombe PB, Ramsey NW: Radioactivity studies on two synovial specimens after radiation synovectomy with yttrium-90 silicate. Ann Rheum Dis 1980;39:87–89.

    PubMed  CAS  Google Scholar 

  9. Chinol M, Vallabhajosula S, Goldsmith SJ, Klein MJ, Deutsch KF, Chinen LK, Brodack JW, Deutsch EA, Watson BA, Tofe AJ: Chemistry and biological behavior of samarium-153-and rhenium-186-labeled hydroxyapatite particles: Potential radiopharmaceuticals for radiation synovectomy. J Nucl Med 1993;34:1536–1542.

    PubMed  CAS  Google Scholar 

  10. Baidoo KE, Lever SZ: Design and synthesis of a versatile precursor to neutral technetium and rhenium complexes. Tetrahedron Lett 1990; 31:5701–5704.

    Article  CAS  Google Scholar 

  11. Troutner DE, Baido KE, Lever SZ, McIlvain HB, Horan PK, Muirhead KM: A rhenium-186 cell binding agent for regional radiotherapy. J Nucl Med 1992;33:899.

    Google Scholar 

  12. Weber DA, Eckerman KF, Dillman LT, Ryman JC (eds): MIRD: Radionuclide Data and Decay Schemes. New York, Society ofNuclear Medicine, 1989.

    Google Scholar 

  13. Davis MA, Chinol M: Radiopharmaceuticals for radiation synovectomy: Evaluation of two yttrium-90 particulate agents. J Nucl Med 1989; 30:1047–1055.

    PubMed  CAS  Google Scholar 

  14. Zalutsky MR, Venkatesan PP, English RJ, Shortkroff S, Sledge CB, Adelstein SJ: Radiation synovectomy with 165 Dy-FHMA: Lymph node uptake and radiation dosimetry calculations. Int J Nucl Med Biol 1986;12:457–465.

    PubMed  CAS  Google Scholar 

  15. 21 Code of Federal Regulations, chapter 1. Part 361—Prescription drugs for human use generally recognized as safe and effective and not misbranded: Drugs used in research, (4-1-92 edition), pp 221–226.

  16. Baker MA, Ohlsson-Wilhelm BM, Carpenter DC, Lorinc RL, Gray BD, Muirhead KA: Linkage of therapeutics to lipophilic agents (Zyn-LinkersTM) enhances biological activity and binds tumor cells in vivo (abstract 2490). 85th Ann Meet Am Assoc for Cancer Research, 1994, p 418.

  17. Gumpel JM, Stevenson AC: Chromosome damage after intra-articular injection of different colloids of yttrium 90. Rheumatol 1975;14:7–12.

    Article  CAS  Google Scholar 

  18. Noble J, Jones AG, Davies MA, Sledge CB, Kramer RI, Livni E: Leakage of radioactive particle systems from a synovial joint studied with a gamma camera. J Bone Joint Surg 1983;65a:381–389.

    Google Scholar 

  19. European Association of Nuclear Medicine: Monograph on [90Y] Yttrium Colloid. Amersham, Amersham Healthcare, 1993, pp 1–2.

    Google Scholar 

  20. Package Insert: Yttrium (90Y) Silicate Injection. Code YAS, 2P. Amersham International Place.

  21. Neves M, Waerenborgh F, Patricio L: Palladium-109 and holmium-166 Potential radionuclides for synoviotherapy —Radiation absorbed dose calculations. Int J Appl Instrum [A] 1987;38:745–749.

    Article  CAS  Google Scholar 

  22. Brill FW, Kopia G, Olzinski AR, McKenney S, Parry TJ, O'Donnell K, Gray BD, Yu J, Burns JF, Muirhead KA: ZynlinkersTM. A novel approach to local site-retention and controlled release of pharmaceutical agents. Proc Int Symp Control Relat Bioact Mater 1994;21:662–663.

    Google Scholar 

  23. Teare GF, Horan PK, Slezak SE, Hay JB: Long-term tracking of lymphocytes in vivo: The migration of PKH-2 labeled lymphocytes. Cell Immunol 1990;134:157–170.

    Article  Google Scholar 

  24. Hugo P, Kappler JW, Godfrey DI, Marrack PC: A cell line that can induce thymocyte positive selection. Nature 1992;360:679–682.

    Article  PubMed  CAS  Google Scholar 

  25. Slezak SE, Horan PK: Fluorescent in vivo tracking of hematopoietic cells. Part I: Technical considerations. Blood 1989;74:2172–2177.

    PubMed  CAS  Google Scholar 

  26. Zeine R, Owens T: Direct demonstration of the infiltration of murine central nervous system (CNS) by Pgp-1/CD44hi CD45RBlow CD4+ cells that induce experimental allergic encephalomyelitis. J Neuroimmunol 1992;40:57–70.

    Article  PubMed  CAS  Google Scholar 

  27. Constant SL, Wilson RA: In vivo lymphocyte responses in the draining lymph nodes of mice exposed toSchistosoma mansoni: Preferential proliferation of T cells is central to the induction of protective immunity. Cell Immunol 1992;139:145–161.

    Article  PubMed  CAS  Google Scholar 

  28. Munn DH, McBride M, Cheung NV: Role of low affinity Fc receptors in antibody dependent tumor cell phagocytosis by human monocyte-derived macrophages. Cancer Res 1991;51:1117–1123.

    PubMed  CAS  Google Scholar 

  29. Basse P, Herberman RB, Nannmark U, et al: Accumulation of adoptively transferred adherent lymphokine-activated killer cells in murine metastases. J Exp Med 1991;174:479–488.

    Article  PubMed  CAS  Google Scholar 

  30. Messina LM, Podrazik RM, Whitehill TA, et al: Adhesion and incorporation oflacZ-transduced endothelial cells into the intact capillary wall in the rat. Proc Natl Acad Sci USA 1992;89:12018–12022.

    Article  PubMed  CAS  Google Scholar 

  31. Wallace PK, Palmer LD, Perry-Lalley D, Bolton ES, Alexander RB, Horan PK, Yang JC, Muirhead KA: Mechanisms of adoptive immunotherapy: Improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells. Cancer Res 1993; 53:2358–2367.

    PubMed  CAS  Google Scholar 

  32. Schlegel RA, Lumley-Sapanski K, Williamson PL: Single cell analysis of factors increasing the survival of resealed erythrocytes in the circulation of mice; in Magnani M, DeLoach JR (eds): The Use of Released Erythrocytes as Carriers and Bioreactors. New York, Plenum 1992, pp 133–138.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Therapeutics Division, Zynaxis, Inc., 371 Phoenixville Pike, 19312, Malvern, PA, USA

    Betsy M. Ohlsson-Wilhelm, Michael R. McDevitt, Brian D. Gray, Robert Lorinc, H. Beal McIlvain, Kamlesh Sheth, Skelly A. Weeks & Katharine A. Muirhead

Authors
  1. Betsy M. Ohlsson-Wilhelm
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael R. McDevitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Brian D. Gray
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert Lorinc
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Beal McIlvain
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kamlesh Sheth
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Skelly A. Weeks
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Katharine A. Muirhead
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ohlsson-Wilhelm, B.M., McDevitt, M.R., Gray, B.D. et al. Zyn-Linker delivery of antirheumatic agents. Immunol Res 13, 82–95 (1994). https://doi.org/10.1007/BF02918270

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02918270

Key Words

Search

Navigation